Hal Barron, Hans Bishop
Grail has appointed Hal Barron and Hans Bishop to its board. Barron is the CSO and president of R&D at GlaxoSmithKline. Prior to that, he served as president of R&D at Calico. He has also held management positions at Roche Pharmaceuticals and Genentech and is associate adjunct professor of epidemiology and biostatistics at the University of California, San Francisco.
Bishop founded Juno Therapeutics in 2013 and was the firm's president and CEO until this past March when it was acquired by Celgene. He previously served as executive-in-residence at Warburg Pincus and is currently on the boards of Agilent Technologies and Celgene.